Fort Washington Investment Advisors Inc. OH Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Fort Washington Investment Advisors Inc. OH raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,726,260 shares of the biopharmaceutical company’s stock after purchasing an additional 39,749 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned 0.13% of Bristol Myers Squibb worth $147,054,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Gateway Investment Advisers LLC lifted its position in shares of Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after buying an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC increased its holdings in Bristol Myers Squibb by 25.9% in the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares in the last quarter. Stephens Inc. AR raised its stake in Bristol Myers Squibb by 13.5% during the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares during the period. Railway Pension Investments Ltd raised its stake in Bristol Myers Squibb by 3.7% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after acquiring an additional 40,300 shares during the period. Finally, Norges Bank purchased a new position in Bristol Myers Squibb during the second quarter valued at approximately $1,554,154,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. HSBC boosted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.41.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $59.40 on Friday. The firm has a market cap of $120.97 billion, a price-to-earnings ratio of 17.22, a P/E/G ratio of 0.17 and a beta of 0.26. The firm has a fifty day moving average price of $58.75 and a 200 day moving average price of $52.11. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the firm posted $1.67 earnings per share. The business’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.